EBITDA Margin: Earnings before interest, taxes, depreciation and amortization as a portion of total revenue. Calculated as: EBITDA / Total Revenues
Axsome Therapeutics, Inc. (AXSM) had EBITDA Margin of -24.49% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$638.50M |
|
$-183.17M |
|
$47.48M |
|
$591.02M |
|
$805.26M |
|
$-166.76M |
|
$-16.94M |
|
$-183.70M |
|
$-183.70M |
|
$-183.17M |
|
$-183.17M |
|
$-183.17M |
|
$-183.17M |
|
$-166.76M |
|
$-156.40M |
|
49.75M |
|
49.75M |
|
$-3.68 |
|
$-3.68 |
|
| Balance Sheet Financials | |
$588.99M |
|
$0.56M |
|
$100.82M |
|
$689.80M |
|
$378.84M |
|
$121.95M |
|
$222.67M |
|
$601.51M |
|
$88.29M |
|
$35.73M |
|
$88.30M |
|
50.88M |
|
| Cash Flow Statement Financials | |
$-93.41M |
|
$-0.48M |
|
$101.47M |
|
$315.35M |
|
$322.93M |
|
$7.58M |
|
$93.75M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.55 |
|
-- |
|
-- |
|
0.58 |
|
2.17 |
|
92.56% |
|
-26.12% |
|
-26.12% |
|
|
EBITDA Margin |
-24.49% |
-28.77% |
|
-28.69% |
|
$-93.89M |
|
-- |
|
-- |
|
-- |
|
0.93 |
|
1.70 |
|
2.84 |
|
128.32 |
|
-207.46% |
|
-512.60% |
|
-26.55% |
|
-87.12% |
|
$1.74 |
|
$-1.89 |
|
$-1.88 |
|